BNT162b2 2024-2025 Vaccine Effectiveness Against COVID-19 in Children Aged 6 Months-17 Years

Area of Science:

• Pediatric infectious diseases
• Vaccinology
• Public health

Background:

• The COVID-19 pandemic continues to pose risks to pediatric populations.
• Assessing vaccine effectiveness in children is crucial for guiding public health strategies.
• The BNT162b2 vaccine is widely used in pediatric age groups.

Purpose of the Study:

• To evaluate the effectiveness of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
• To assess vaccine effectiveness against symptomatic COVID-19, hospitalization, and emergency/urgent care visits in children.
• To analyze effectiveness across different pediatric age strata.

Main Methods:

• A test-negative case-control study design was employed.
• The study included a large cohort of children aged 6 months to 17 years.
• Data were collected from Kaiser Permanente Southern California.

Main Results:

• BNT162b2 effectiveness against hospitalization/emergency department/urgent care/outpatient visits was 36% (95% CI: -5-61%) in children aged 6 months-4 years.
• Effectiveness was 42% (95% CI: -2-67%) in children aged 5-17 years.
• These findings suggest a protective benefit of the vaccine.

Conclusions:

• Pediatric COVID-19 vaccination with BNT162b2 provides a beneficial effect against severe clinical outcomes.
• The vaccine demonstrates continued relevance for protecting children against COVID-19-related healthcare utilization.
• Ongoing surveillance and vaccination efforts are important for pediatric populations.